Actively Recruiting
Adaptive Phase 2b3 Study Comparing Povetacicept and Tacrolimus for Primary Membranous Nephropathy Treatment
Led by Vertex Pharmaceuticals Incorporated · Updated on 2026-10-30
176
Participants Needed
117
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating povetacicept for its efficacy, safety, and tolerability in people with primary membranous nephropathy pMN, a kidney condition. This Phase 2b3 adaptive, randomized study compares povetacicept with the calcineurin inhibitor tacrolimus to determine which treatment better supports clinical remission of pMN. Participants will be randomly assigned to receive one of two doses of povetacicept, given as a subcutaneous injection, or tacrolimus capsules taken orally. The study includes sequential phases, with dosing based on previous phase results. Participants will receive their assigned treatment and be monitored throughout the study. During participation, individuals will be assessed for clinical remission at 104 weeks, and safety will be monitored up to 112 weeks by tracking adverse events. Researchers will conduct regular evaluations to measure how well the treatments work and their tolerability. The total study duration extends up to nearly four years, with ongoing monitoring and data collection.
CONDITIONS
Brief Title
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Research Team
M
Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here